Systemic juvenile idiopathic arthritis (SJIA) is an inflammatory condition characterized by fever, lymphadenopathy, arthritis, rash and serositis. Systemic inflammation has been associated with dysregulation of the innate immune system, suggesting that SJIA is an autoinflammatory disorder. IL-1 and IL-6 play a major role in the pathogenesis of SJIA, and treatment with IL-1 and IL-6 inhibitors has shown to be highly effective. However, complications of SJIA, including macrophage activation syndrome, limitations in functional outcome by arthritis and long-term damage from chronic inflammation, continue to be a major issue in SJIA patients' care. Translational research leading to a profound understanding of the cytokine crosstalk in SJIA and the identification of risk factors for SJIA complications will help to improve long-term outcome.

Complications of systemic juvenile idiopathic arthritis : risk factors and management recommendations / A. Woerner, A. Von Scheven-Gête, R. Cimaz, M. Hofer. - In: EXPERT REVIEW OF CLINICAL IMMUNOLOGY. - ISSN 1744-666X. - 11:5(2015), pp. 575-588. [10.1586/1744666X.2015.1032257]

Complications of systemic juvenile idiopathic arthritis : risk factors and management recommendations

R. Cimaz;
2015

Abstract

Systemic juvenile idiopathic arthritis (SJIA) is an inflammatory condition characterized by fever, lymphadenopathy, arthritis, rash and serositis. Systemic inflammation has been associated with dysregulation of the innate immune system, suggesting that SJIA is an autoinflammatory disorder. IL-1 and IL-6 play a major role in the pathogenesis of SJIA, and treatment with IL-1 and IL-6 inhibitors has shown to be highly effective. However, complications of SJIA, including macrophage activation syndrome, limitations in functional outcome by arthritis and long-term damage from chronic inflammation, continue to be a major issue in SJIA patients' care. Translational research leading to a profound understanding of the cytokine crosstalk in SJIA and the identification of risk factors for SJIA complications will help to improve long-term outcome.
Anakinra; Biological agents; Canakinumab; Macrophage activation syndrome; Risk factors; Systemic juvenile idiopathic arthritis; Tocilizumab; Animals; Antibodies; Monoclonal; Antibodies; Monoclonal; Humanized; Arthritis; Juvenile; Humans; Immunity; Innate; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Interleukin-6; Macrophage Activation; Risk Factors; Translational Medical Research; Immunology and Allergy; Immunology; Medicine (all)
Settore MED/16 - Reumatologia
2015
Article (author)
File in questo prodotto:
File Dimensione Formato  
ExpRevWoerner2015.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.06 MB
Formato Adobe PDF
1.06 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/664727
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 16
social impact